|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Lymphoma
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin's lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin's lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin's lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin's and non-Hodgkin's lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer. [Source: www.cancer.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Mantle Cell Lymphoma Study CRAD001N2201
The purpose of this clinical trial is to determine if the study drug RAD001 (everolimus) is safe and effective in people with a specific cancer of the lymph nodes, called mantle cell lymphoma, which has worsened despite treatment. The goal is to learn if the study drug RAD001 can slow the progression of mantle cell lymphoma in participants. The harmful effects of the study drug RAD001 will also be evaluated. A “study drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 2 Participation Duration: Participants will be required to visit the study doctor twice per month during the first 3 months and, then every 28 days until treatment with the study drug is finished. Protocol Number: CRAD001N2201 Hodgkins Lymphoma Study CLBH589E2214
The purpose of this clinical research study is to determine the effectiveness of the investigational drug panobinostat on participants with relapsed or refractory Hodgkin’s Lymphoma that has not improved or has worsened with other treatments. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 2 Participation Duration: Qualifying participants will be required to visit the study center 2-3 times during the first week, to receive medication and for an evaluation. In weeks 2 and 3, participants will be required to visit the study facility once a week for an evaluation. After week 3, the participant will be asked to come to the clinic 2 times within each 21 day cycle. Each visit should take approximately 1-3 hours. Protocol Number: CLBH589E2214 |